| Novel genetic variants in carboxylesterase 1 predict severe early‐onset capecitabine‐related toxicity S Hamzic, D Kummer, S Milesi, D Mueller, M Joerger, S Aebi, U Amstutz, ... Clinical Pharmacology & Therapeutics 102 (5), 796-804, 2017 | 55 | 2017 |
| Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy. S Hamzic, S Aebi, M Joerger, M Montemurro, M Ansari, U Amstutz, ... Swiss medical weekly 150, w20375, 2020 | 45 | 2020 |
| Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis S Hamzic, D Kummer, TK Froehlich, M Joerger, S Aebi, C Palles, ... Pharmacological research 152, 104594, 2020 | 34 | 2020 |
| Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity … S Hamzic, D Schärer, SM Offer, D Meulendijks, C Nakas, RB Diasio, ... British journal of clinical pharmacology 87 (8), 3234-3243, 2021 | 31 | 2021 |
| Predicting in vivo compound brain penetration using multi-task graph neural networks S Hamzic, R Lewis, S Desrayaud, C Soylu, M Fortunato, G Gerebtzoff, ... Journal of chemical information and modeling 62 (13), 3180-3190, 2022 | 18 | 2022 |
| Come a long way, still a ways to go: from predicting and preventing fluoropyrimidine toxicity to increased efficacy? S Hamzic, U Amstutz, CR Largiadèr Pharmacogenomics 19 (8), 689-692, 2018 | 8 | 2018 |
| A novel nomenclature for repeat motifs in the thymidylate synthase enhancer region and its relevance for pharmacogenetic studies D Schaerer, TK Froehlich, S Hamzic, SM Offer, RB Diasio, M Joerger, ... Journal of personalized medicine 10 (4), 181, 2020 | 7 | 2020 |
| The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity S Hamzic, N Wenger, TK Froehlich, M Joerger, S Aebi, CR Largiadèr, ... The pharmacogenomics journal 17 (4), 319-324, 2017 | 4 | 2017 |
| 1178 Association between polygenic risk for thyroid dysfunction, derived from tumor panel sequencing, immune-related thyroid toxicity and overall survival in ICI treated NSCLC … E Ebot, D Bray, C Adams, D Jin, P Kreutzfeldt-Jensen, R Mohindra, ... Journal for ImmunoTherapy of Cancer 12 (Suppl 2), 2024 | | 2024 |
| METHODS RESULTS RESULTS E Ebot, D Bray, C Adams, D Jin, P Kreutzfeldt-Jensen, R Mohindra, ... | | |
